Vivo Capital, LLC — 13F Holdings & Portfolio
CIK 1674712 · latest 13F-HR filed 2026-08-14
Vivo Capital, LLC manages $1.10B in 13F-reported U.S. long-equity assets across 47 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are TRVI (8.68%), PRAX (8.29%), ERAS (6.90%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 7 new positions, exited 6, added to 16, and trimmed 16.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$1.10B
Long-equity book
47
Distinct positions
2026-06-30
Filed 2026-08-14
+7 / −6 / ↑16 / ↓16
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Share-count changes vs the prior 13F.
Top Adds (vs prior quarter)
- Arrivent BioPharma Inc$38.0M +185.9%
- Trevi Therapeutics Inc$34.2M +56.3%
- Tenax Therapeutics Inc$33.0M +991.9%
- Abivax SA - ADR$28.6M +107.3%
- Aclaris Therapeutics, Inc.$10.4M +41.7%
Top Trims
- Erasca Inc-$121.0M -61.5%
- Compass Therapeutics Inc-$33.5M -66.4%
- DBV Technologies SA-$25.5M -45.7%
- Praxis Precision Medicines-$18.4M -16.9%
- SAB Biotherapeutics Inc-$15.3M -34.9%
New Positions
- Achieve Life Sciences Inc.$18.0M
- Editas Medicine Inc$11.5M
- Odyssey Therapeutics Inc$10.8M
- Aura Biosciences Inc$8.3M
- Avalo Therapeutics Inc$5.1M
Exited Positions
- Terns Pharmaceuticals Inc$70.4M
- Veradermics Inc$18.9M
- Cogent Biosciences Inc$16.3M
- Soleno Therapeutics Inc$9.9M
- Viridian Therapeutics Inc$3.3M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Trevi Therapeutics Inc | TRVI | 89532M101 | $95.0M | 8.68% | 5,094,668 | SH |
| 2 | Praxis Precision Medicines | PRAX | 74006W207 | $90.8M | 8.29% | 271,116 | SH |
| 3 | Erasca Inc | ERAS | 29479A108 | $75.6M | 6.90% | 4,127,412 | SH |
| 4 | Arrivent BioPharma Inc | AVBP | 04272N102 | $58.4M | 5.34% | 1,682,097 | SH |
| 5 | Abivax SA - ADR | ABVX | 00370M103 | $55.3M | 5.05% | 414,899 | SH |
| 6 | Tango Therapeutics Inc | TNGX | 87583X109 | $43.1M | 3.94% | 1,379,769 | SH |
| 7 | Corvus Pharmaceuticals Inc | CRVS | 221015100 | $41.9M | 3.83% | 2,805,816 | SH |
| 8 | Bright Minds Biosciences Inc | DRUG | 10919W405 | $39.1M | 3.57% | 557,172 | SH |
| 9 | Sinovac Biotech Ltd. | SVA | P8696W104 | $38.2M | 3.49% | 5,903,000 | SH |
| 10 | Tenax Therapeutics Inc | TENX | 88032L605 | $36.4M | 3.32% | 2,500,000 | SH |
| 11 | Aclaris Therapeutics, Inc. | ACRS | 00461U105 | $35.4M | 3.23% | 6,694,637 | SH |
| 12 | Dyne Therapeutics Inc | DYN | 26818M108 | $34.6M | 3.16% | 1,557,466 | SH |
| 13 | Dianthus Therapeutics Inc | DNTH | 252828108 | $34.5M | 3.15% | 353,998 | SH |
| 14 | Alto Neuroscience Inc | ANRO | 02157Q109 | $31.9M | 2.91% | 1,208,858 | SH |
| 15 | DBV Technologies SA | DBVT | 23306J309 | $30.3M | 2.76% | 1,844,758 | SH |
| 16 | SAB Biotherapeutics Inc | SABS | 78397T202 | $28.5M | 2.60% | 7,299,909 | SH |
| 17 | Moonlake Immunotherapeutics | MLTX | 61559X104 | $27.3M | 2.49% | 1,400,000 | SH |
| 18 | LB Pharmaceuticals Inc | LBRX | 50180M108 | $26.0M | 2.37% | 800,000 | SH |
| 19 | Minerva Neurosciences Inc | NERV | 603380205 | $24.0M | 2.19% | 4,322,747 | SH |
| 20 | Design Therapeutics Inc | DSGN | 25056L103 | $23.3M | 2.13% | 1,612,903 | SH |
| 21 | Oric Pharmaceuticals Inc | ORIC | 68622P109 | $20.0M | 1.83% | 1,848,786 | SH |
| 22 | CAMP4 Therapeutics Corporation | CAMP | 13463J101 | $18.6M | 1.69% | 4,246,568 | SH |
| 23 | Faeth Therapeutics Inc | FTH | 81728A207 | $18.1M | 1.65% | 722,020 | SH |
| 24 | Achieve Life Sciences Inc. | ACHV | 004468500 | $18.0M | 1.64% | 2,751,032 | SH |
| 25 | Compass Therapeutics Inc | CMPX | 20454B104 | $17.0M | 1.55% | 7,757,060 | SH |
| 26 | AN2 Therapeutics Inc | ANTX | 037326105 | $15.3M | 1.39% | 3,153,640 | SH |
| 27 | Editas Medicine Inc | EDIT | 28106W103 | $11.5M | 1.05% | 3,555,250 | SH |
| 28 | Geron Corp | GERN | 374163103 | $11.1M | 1.01% | 8,671,797 | SH |
| 29 | Odyssey Therapeutics Inc | ODTX | 67613T104 | $10.8M | 0.98% | 575,000 | SH |
| 30 | Eupraxia Pharmaceuticals Inc | EPRX | 29842P105 | $8.9M | 0.81% | 1,350,000 | SH |
| 31 | Onkure Therapeutics Inc | OKUR | 68277Q105 | $8.8M | 0.80% | 1,927,710 | SH |
| 32 | Olema Pharmaceuticals Inc | OLMA | 68062P106 | $8.4M | 0.77% | 671,843 | SH |
| 33 | Monopar Therapeutics Inc | MNPR | 61023L207 | $8.4M | 0.77% | 90,500 | SH |
| 34 | Aura Biosciences Inc | AURA | 05153U107 | $8.3M | 0.76% | 1,166,667 | SH |
| 35 | Surrozen Inc | SRZN | 86889P208 | $6.7M | 0.62% | 260,000 | SH |
| 36 | ALX Oncology Holdings Inc | ALXO | 00166B105 | $6.6M | 0.60% | 3,184,713 | SH |
| 37 | Satellos Bioscience Inc | MSLE | 80401L803 | $6.3M | 0.58% | 813,666 | SH |
| 38 | Avalo Therapeutics Inc | AVTX | 05338F306 | $5.1M | 0.46% | 275,000 | SH |
| 39 | Pepgen Inc | PEPG | 713317105 | $4.2M | 0.38% | 2,325,000 | SH |
| 40 | Valneva SE | VALN | 92025Y103 | $4.0M | 0.36% | 763,199 | SH |
| 41 | Sera Prognostics Inc | SERA | 81749D107 | $3.0M | 0.27% | 1,650,440 | SH |
| 42 | Unicycive Therapeutics | UNCY | 90466Y202 | $2.6M | 0.24% | 550,000 | SH |
| 43 | Instil Bio Inc | TIL | 45783C200 | $2.3M | 0.21% | 292,743 | SH |
| 44 | InMed Pharmaceuticals Inc | INM | 457637700 | $1.2M | 0.11% | 798,377 | SH |
| 45 | Bolt Biotherapeutics Inc | BOLT | 097702203 | $278.8K | 0.03% | 72,414 | SH |
| 46 | Pasithea Therapeutics Corp | KTTA | 70261F202 | $239.9K | 0.02% | 465,471 | SH |
| 47 | Precision Biosciences Inc | DTIL | 74019P207 | $36.7K | 0.00% | 4,675 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $1.10B | 47 | 0001213900-26-089935 |
| 2026-03-31 | 2026-05-15 | $1.20B | 45 | 0001213900-26-057929 |
| 2026-03-31 | 2026-05-20 | $1.20B | 46 | 0001213900-26-059247 |
| 2025-12-31 | 2026-02-13 | $1.55B | 47 | 0001213900-26-016236 |
| 2025-09-30 | 2025-11-14 | $1.24B | 47 | 0001213900-25-110767 |
PALO ALTO, CA 94301